Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 7, 2020-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials